Proton Capital Corp. (TSXV:PTN.P) entered into a letter of intent to acquire Pharmachoice on April 20, 2023. Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable pursuant to TSXV Requirements, majority of the minority shareholder approval and is subject to the execution of Definitive Agreements and the conditions contained therein.

As of July 26, 2023, Proton is pleased to provide an update to the Qualifying Transaction and announces that it is considering an equity financing. Proton advises that it has not yet entered into any agreement, letter of intent, term sheet or other arrangement in relation to the Potential Financing. On August 31, 2023, the definitive agreements in relation to a strategic alliance with PharmaChoice Canada Inc. were executed.